Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind …
A Deodhar, PS Helliwell, WH Boehncke, AP Kollmeier… - The Lancet, 2020 - thelancet.com
Background Many patients with psoriatic arthritis have an inadequate response to tumor
necrosis factor (TNF) inhibitors. Guselkumab, a specific inhibitor of interleukin-23 (IL-23) via IL-…
necrosis factor (TNF) inhibitors. Guselkumab, a specific inhibitor of interleukin-23 (IL-23) via IL-…
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
PJ Mease, P Rahman, AB Gottlieb, AP Kollmeier… - The Lancet, 2020 - thelancet.com
Background The interleukin-23 (IL-23)/T-helper 17 cell pathway is implicated in psoriatic
arthritis pathogenesis. Guselkumab, an IL-23 inhibitor that specifically binds the IL-23 p19 …
arthritis pathogenesis. Guselkumab, an IL-23 inhibitor that specifically binds the IL-23 p19 …
Long‐term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin‐23, through two years: Results from a phase III …
…, AB Gottlieb, EC Hsia, AP Kollmeier… - Arthritis & …, 2022 - Wiley Online Library
Objective To assess long‐term efficacy and safety of guselkumab, an interleukin‐23 p19
subunit (IL‐23p19) inhibitor, in patients with active psoriatic arthritis (PsA) from the phase III …
subunit (IL‐23p19) inhibitor, in patients with active psoriatic arthritis (PsA) from the phase III …
Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER …
…, X Baraliakos, SD Chakravarty, AP Kollmeier… - The Lancet …, 2021 - thelancet.com
Background Guselkumab was efficacious in reducing signs and symptoms of psoriatic arthritis
in the phase 3 DISCOVER-1 and DISCOVER-2 studies. We aimed to evaluate the efficacy …
in the phase 3 DISCOVER-1 and DISCOVER-2 studies. We aimed to evaluate the efficacy …
Efficacy and safety of guselkumab, an interleukin‐23p19–specific monoclonal antibody, through one year in biologic‐naive patients with psoriatic arthritis
…, AB Gottlieb, EC Hsia, AP Kollmeier… - Arthritis & …, 2021 - Wiley Online Library
Objective Guselkumab, a human monoclonal antibody specific to interleukin‐23p19,
demonstrated efficacy and safety versus placebo through week 24 of the phase III DISCOVER‐2 …
demonstrated efficacy and safety versus placebo through week 24 of the phase III DISCOVER‐2 …
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III …
…, WH Boehncke, ER Soriano, EC Hsia, AP Kollmeier… - RMD open, 2021 - rmdopen.bmj.com
Objective Evaluation of the efficacy and safety of guselkumab, a human monoclonal antibody
targeting the interleukin-23p19 subunit, in patients with psoriatic arthritis (PsA) through 1 …
targeting the interleukin-23p19 subunit, in patients with psoriatic arthritis (PsA) through 1 …
[HTML][HTML] Pooled safety results through 1 year of 2 phase III trials of guselkumab in patients with psoriatic arthritis
…, PJ Mease, AB Gottlieb, S Kafka, AP Kollmeier… - The Journal of …, 2021 - jrheum.org
Objective Evaluate the safety of guselkumab (monoclonal antibody targeting interleukin [IL]-23p19)
in patients with psoriatic arthritis (PsA) through 1 year (1Y) of the phase III DISCOVER…
in patients with psoriatic arthritis (PsA) through 1 year (1Y) of the phase III DISCOVER…
[HTML][HTML] Collagen turnover biomarkers associate with active psoriatic arthritis and decrease with guselkumab treatment in a phase 3 clinical trial (DISCOVER-2)
…, SH Nielsen, S Gao, EC Hsia, AP Kollmeier… - Rheumatology and …, 2022 - Springer
Introduction Guselkumab, a novel interleukin-23p19 subunit monoclonal antibody, has been
shown to effectively improve the diverse manifestations of active psoriatic arthritis (PsA) in …
shown to effectively improve the diverse manifestations of active psoriatic arthritis (PsA) in …
[HTML][HTML] Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of …
…, L Gossec, A Kavanaugh, AP Kollmeier… - Arthritis research & …, 2021 - Springer
Background The interleukin-23p19-subunit inhibitor guselkumab effectively treats signs and
symptoms of psoriatic arthritis (PsA). We evaluated the effect of guselkumab on fatigue. …
symptoms of psoriatic arthritis (PsA). We evaluated the effect of guselkumab on fatigue. …
[HTML][HTML] Long-term safety of guselkumab in patients with psoriatic disease: an integrated analysis of eleven phase II/III clinical studies in psoriasis and psoriatic arthritis
…, A Deodhar, E Leibowitz, K Rowland, AP Kollmeier… - Drug Safety, 2024 - Springer
Introduction The benefit/risk profiles of biologics can be affected by comorbidities, certain
demographic characteristics, and concomitant medications; therefore, it is important to evaluate …
demographic characteristics, and concomitant medications; therefore, it is important to evaluate …